Vasoconstrictor therapy (specially terlipressin) and volume expansion (with albumin) is the recommended treatment of choice for the hepatorenal syndrome (HRS)-AKI to counteract systemic arterial vasodilation and hypovolemia. This evidence concerns the gene ALB and Renal insufficiency.